ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Phio Pharmaceuticals Corporation

Phio Pharmaceuticals Corporation (PHIO)

2.27
-0.20
(-8.10%)
2.2101
-0.0599
(-2.64%)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
2.2101
Bid
2.00
Ask
25.00
Volume
263,189
2.20 Day's Range 2.475
0.9657 52 Week Range 9.79
Market Cap
Previous Close
2.47
Open
2.41
Last Trade
20
@
2.32
Last Trade Time
Financial Volume
$ 611,101
VWAP
2.3219
Average Volume (3m)
3,428,382
Shares Outstanding
1,055,000
Dividend Yield
-
PE Ratio
-0.33
Earnings Per Share (EPS)
-6.78
Revenue
-
Net Profit
-7.15M

About Phio Pharmaceuticals Corporation

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipelin... Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Camden, Delaware, USA
Founded
-
Phio Pharmaceuticals Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PHIO. The last closing price for Phio Pharmaceuticals was $2.47. Over the last year, Phio Pharmaceuticals shares have traded in a share price range of $ 0.9657 to $ 9.79.

Phio Pharmaceuticals currently has 1,055,000 shares outstanding. The market capitalization of Phio Pharmaceuticals is $2.61 million. Phio Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.33.

PHIO Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3299-12.98818897642.543.24972.218219872.79975332CS
40.450125.57386363641.763.24971.717122182.46391581CS
120.870164.93283582091.343.24970.965734283821.70602691CS
26-0.6599-22.99303135892.879.790.965748390624.18296326CS
52-4.2699-65.89351851856.489.790.965724215074.17525978CS
156-69.0699-96.899410774471.28110.430.965710618579.87438505CS
260-250.5099-99.1254748338252.72470.880.9657103715497.94666875CS

PHIO - Frequently Asked Questions (FAQ)

What is the current Phio Pharmaceuticals share price?
The current share price of Phio Pharmaceuticals is $ 2.2101
How many Phio Pharmaceuticals shares are in issue?
Phio Pharmaceuticals has 1,055,000 shares in issue
What is the market cap of Phio Pharmaceuticals?
The market capitalisation of Phio Pharmaceuticals is USD 2.61M
What is the 1 year trading range for Phio Pharmaceuticals share price?
Phio Pharmaceuticals has traded in the range of $ 0.9657 to $ 9.79 during the past year
What is the PE ratio of Phio Pharmaceuticals?
The price to earnings ratio of Phio Pharmaceuticals is -0.33
What is the reporting currency for Phio Pharmaceuticals?
Phio Pharmaceuticals reports financial results in USD
What is the latest annual profit for Phio Pharmaceuticals?
The latest annual profit of Phio Pharmaceuticals is USD -7.15M
What is the registered address of Phio Pharmaceuticals?
The registered address for Phio Pharmaceuticals is 2140 S DUPONT HWY, CAMDEN, DELAWARE, 19934
What is the Phio Pharmaceuticals website address?
The website address for Phio Pharmaceuticals is www.phiopharma.com
Which industry sector does Phio Pharmaceuticals operate in?
Phio Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RBNERobin Energy Ltd
$ 13.85
(313.43%)
101.81M
OPOceanPal Inc
$ 1.63
(125.45%)
80.28M
LGHLWLion Group Holding Ltd
$ 0.0052
(116.67%)
6.87M
NEONNeonode Inc
$ 16.83
(68.47%)
4.78M
ICONIcon Energy Corporation
$ 2.90
(62.01%)
59.04M
SBETSharpLink Gaming Inc
$ 9.2275
(-71.63%)
41.92M
AIHSSenmiao Technology Ltd
$ 0.381
(-63.01%)
16.8M
CHSNChanson International Holding
$ 0.22
(-60.00%)
15.15M
KWMK Wave Media Ltd
$ 2.91
(-50.43%)
2.59M
JZXNJiuzi Holdings Inc
$ 1.56
(-46.39%)
2.24M
HCTIHealthcare Triangle Inc
$ 0.0201
(-33.00%)
856.89M
GNLNGreenlane Holdings Inc
$ 0.0101
(-34.42%)
792.34M
CGBSCrown LNG Holdings Ltd
$ 0.1104
(31.43%)
788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.655
(3.81%)
246.13M
NVDANVIDIA Corporation
$ 141.97
(-2.09%)
180.81M

PHIO Discussion

View Posts
Spuds McKenz66 Spuds McKenz66 1 week ago
great day Capp
👍️0
bcapps66 bcapps66 1 week ago
Fo sho!
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
cool Lover Nice
👍️0
subslover subslover 1 week ago
Good for a few bones, spuds.
'Buy' rating from H.C. Wainwright, alongside a price target of $14.
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
we are close on calls think I'm up one or 2 on you , I got DJT next call PHIO dam 14 target r u sure Lover?
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
nice call Lover
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
ya I knew u have been telling me for a while now lol
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
got some DJT figure it will hit 30 soon PHIO is the bomb
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
3 amigos me Capp and Lover know what to buy
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
looking good Capp
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
cool
👍️0
subslover subslover 1 week ago
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
Newsfile Corp.
Newsfile Corp
- Robert Infarinato named VP, Strategic Development

- Lisa Carson named as new VP, Finance and Administration

Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to treat cancer. Phio announced today a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds. Recently, positive interim safety and efficacy results were reported in the on-going Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer. Clinical and preclinical data to date suggest promise for other potential applications across the INTASYL portfolio.

Mr. Robert Infarinato has been appointed to the role of VP, Strategic Development, effective June 9, 2025. He will be transitioning from his role as Chief Financial Officer to concentrate on directing strategic business development initiatives focusing on potential applications of the broader INTASYL portfolio. Concurrently, Ms. Lisa Carson, was appointed VP, Finance and Administration and will lead Phio's finance team.

Mr. Infarinato has over 30 years of finance and accounting leadership experience. He served as head of a consulting firm, advising on operational matters including funding and IPO process. Previous positions include serving as Chairman of the Board of Trustees for Abington Health and as executive Vice President and CFO of an international service company.

Ms. Carson joined Phio in May 2025 with more than 20 years of finance and accounting leadership experience. She most recently was VP, Finance and Controller at Prelude Therapeutics, where she supported the company's IPO and expansion. Ms. Carson also held leadership roles at TELA Bio and PhaseBio Pharmaceuticals.

"It is a great pleasure to announce the new positions of these two experienced professionals," said Robert Bitterman, Phio's CEO and President. "This strategic move underscores the company's commitment to gain greater awareness of the potential applications in our INTASYL siRNA portfolio."
👍️0
subslover subslover 1 week ago
I have always liked this baby!😍
👍 1
ollik78 ollik78 1 week ago
Pretty 😍 
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
ok Capp thanks
👍️0
bcapps66 bcapps66 1 week ago
I'm in too. You should take a look at $HSDT as a bounce play. Low float even with the recent offering.
👍️ 1
work-n-hard work-n-hard 1 week ago
👍️0
81vette 81vette 1 week ago
Thanks !! Appreciate you!
👍️ 1
work-n-hard work-n-hard 1 week ago
Believe this one is going to go again. Just a heads up while folks are not looking. lol
👍️0
work-n-hard work-n-hard 1 week ago
PHIO showing some energy this morning.
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
I'LL go in with 2k shares y not PHIO
👍️0
Spuds McKenz66 Spuds McKenz66 1 week ago
wowzer bowzer FEE FI FOE PHIO
👍️0
subslover subslover 1 week ago
$14.00 price target. Phio Pharmaceuticals (PHIO) Gains 'Buy' Rating with Promising Price Target | PHIO Stock News

https://www.gurufocus.com/news/2909672/phio-pharmaceuticals-phio-gains-buy-rating-with-promising-price-target-phio-stock-news
👍 1
Spuds McKenz66 Spuds McKenz66 1 month ago
ok cool I need PLUG to come to bear fruit
👍️0
subslover subslover 1 month ago
$PHIO is one of my favorite biotech plays!😁
👍️0
Spuds McKenz66 Spuds McKenz66 1 month ago
ya lover all good
👍️0
subslover subslover 1 month ago
OT: I just started buying PLUG and now messaged you on their thread—amazing 1/2 billion $ line of credit.
👍️0
Spuds McKenz66 Spuds McKenz66 1 month ago
ya insane
👍️0
subslover subslover 1 month ago
OT: Did you read this huge PLUG release? Plug Power Closes $525 Million Secured Credit Facility with Yorkville Advisors
Plug to Hold First Quarter 2025 Earnings Call on May 12, 2025
SLINGERLANDS, N.Y., May 06, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions, today announced the initial closing of its previously announced $525 million secured term loan facility with Yorkville Advisors. The initial tranche in an aggregate principal amount of $210 million was drawn and funded. Commensurate with establishing this facility, the company has retired $82.5 million in aggregate principal of the existing convertible debenture with Yorkville Advisors, which had approximately 55 million associated underlying shares given the conversion price, and therefore this refinancing has reduced potential dilution. The transaction enhances Plug’s liquidity position and provides the company with additional financial flexibility as it continues to scale its green hydrogen network and drive toward profitability.

“This financing provides meaningful capital to support Plug’s strategic priorities in 2025 and beyond,” said Andy Marsh, CEO of Plug. “We appreciate the confidence Yorkville has shown in our long-term vision and are pleased to have closed this deal under favorable terms for the company.”

Plug will provide further details during its upcoming first quarter 2025 earnings call.

Q1 2025 Earnings Conference Call Details:

Plug’s First Quarter 2025 results will be released on Monday, May 12, 2025.

Join the call

Time: 4:30 pm ET
Participant Dial-In: 877-407-9221 / +1 201-689-8597
Webcast: https://event.webcasts.com/starthere.jsp?ei=1718659&tp_key=e4fec597b7
A live webcast will be available on the Plug Investor Relations website at https://www.ir.plugpower.com, and a playback will be available online for a period of time following the call.
👍️0
Spuds McKenz66 Spuds McKenz66 1 month ago
cool into PLUG i am watching
👍️0
subslover subslover 1 month ago
EXCELLENT! This cancer research shows much promise! ♥️ 😇
👍️0
Spuds McKenz66 Spuds McKenz66 1 month ago
heavy in PLUG 100K
👍️0
subslover subslover 1 month ago
Here you go Spuds buddy = Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Newsfile Corp.
Newsfile Corp
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort
Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10th
Marlborough, Massachusetts--(Newsfile Corp. - May 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a complete pathologic response (100% tumor clearance) has been reported for 2 of 3 patients with cutaneous squamous cell carcinoma (cSCC) treated in the third dose cohort. The third patient was reported as having a pathologic non-response (
👍️0
glenn1919 glenn1919 1 month ago
PHIO...........................................p/m
👍️0
work-n-hard work-n-hard 2 months ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176074282
👍️0
81vette 81vette 2 months ago
Lol
👍️0
work-n-hard work-n-hard 2 months ago
Color me crazy....again. 2.23 it's like it was talking to me with it's eyes. lol
👍️0
subslover subslover 2 months ago
See the % gains here, Spuds! We're pushing $3 :) The strength of the team is each individual member. The strength of each member is the team.😍♥️
👍️0
work-n-hard work-n-hard 2 months ago
I started to scan for something before leaving out and thought I'd just check my watchlist and this one was there. So lucky for that.
GLTU 81

PS: I had a 89 for a few years. Love that they already had a 6 spd at that time. That was something new for me back then.
I wasn't used to getting over 100mph and still have 2 gears left. 🤪
👍️0
81vette 81vette 2 months ago
PHIO,nice grab! I should have bought it yesterday but I wanted 3 solder candles for confirmation of run continue not a pump and dump on no news,bought on the only dip in death hr,had many bids in(2.54 only filled)
Maybe news and a gap up to $10 tomorrow is going to be the hype,hope,fomo.
No shares showing up to short is promising,solid zb,it does hint big news coming if they won’t loan out their shares to short
Good skill to you bro!
👍️0
work-n-hard work-n-hard 2 months ago
Jumped into this one about 7:05 this morning @ 2.23 and had to run out.
Just added 2.87
👍️0
81vette 81vette 2 months ago
PHIO going for nhod in death hr,moving freely on low vol,expect vol surges soon that increase,has gapped to $10 before so greed could be strong,also skin cancer cure for potential
👍️0
81vette 81vette 2 months ago
bids filling,ZB/126%fee(no rebate)charting up,moving freely
👍️0
make it happen make it happen 2 months ago
Spending 150% of cash how much burn is going to be needed to finish phase 2 and phase 3 and get fda approvals and then distribution and a lot of other fees expenses and hopefully works if does hell yeah will be bought by another company imo but won't be for a long time and have to do more R&D. then the company technically will only have a paycheck.
👍️0
subslover subslover 2 months ago
"You bet your sweet bippy" 🥰
👍️ 2 🤭 1
Spuds McKenz66 Spuds McKenz66 2 months ago
Nice move PHIO
👍️0
subslover subslover 2 months ago
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Newsfile Corp.
Newsfile Corp
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration

Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio's Phase 1b clinical trial (NCT 06014086) for Phio's lead product candidate, PH-762.

Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This trial assesses the tumor response and determines the recommended dose for further study of PH-762. In the third cohort of this trial, three patients with cutaneous squamous cell carcinoma were enrolled. For these patients, injections were well tolerated with no serious adverse events and there were no dose-limiting toxicities. Pathology results related to efficacy of PH-762 in the third cohort are forthcoming.

"We are impressed with the continuing safety profile of PH-762 having now progressed through the first 3 escalating doses," said Mary Spellman, MD, Phio's acting Chief Medical Officer.

Previously, seven patients diagnosed with cutaneous carcinomas were treated in dose cohorts 1 and 2. The second cohort enrolled a total of 4 patients who were diagnosed with cutaneous squamous cell carcinoma. At Day 36 (tumor excision) in the second cohort, two patients had a complete response (100% tumor clearance), and one patient had a partial response (90% clearance). All three patients in cohort 1 and one patient in cohort 2 maintained stable disease.

"We are optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer," said Robert Bitterman, President and CEO of Phio Pharmaceuticals.

About Phio Pharmaceuticals Corp.
👍️0
Spuds McKenz66 Spuds McKenz66 2 months ago
lol made nothing today ahh lost 200
👍️0
subslover subslover 2 months ago
LMFAO!🤣 and I always thought it was the other way around!🤑😋
👍️0
Spuds McKenz66 Spuds McKenz66 2 months ago
i make a grand a day 5 days and then jack off
👍️0

Your Recent History

Delayed Upgrade Clock